StockNews.com Upgrades Abeona Therapeutics (NASDAQ:ABEO) to “Hold”

StockNews.com upgraded shares of Abeona Therapeutics (NASDAQ:ABEO) from a sell rating to a hold rating in a report issued on Monday morning.

Several other analysts have also recently weighed in on ABEO. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a report on Monday. Oppenheimer initiated coverage on shares of Abeona Therapeutics in a report on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $17.50.

Abeona Therapeutics Stock Down 0.2 %

Shares of NASDAQ ABEO opened at $4.99 on Monday. The stock has a market cap of $216.92 million, a P/E ratio of -1.86 and a beta of 1.79. The business’s fifty day simple moving average is $5.43 and its 200-day simple moving average is $5.82. Abeona Therapeutics has a 12-month low of $3.05 and a 12-month high of $8.45. The company has a current ratio of 6.12, a quick ratio of 6.12 and a debt-to-equity ratio of 0.31.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.19. As a group, equities analysts predict that Abeona Therapeutics will post -1.16 EPS for the current fiscal year.

Institutional Investors Weigh In On Abeona Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Twinbeech Capital LP acquired a new stake in shares of Abeona Therapeutics during the fourth quarter worth about $58,000. Squarepoint Ops LLC purchased a new stake in Abeona Therapeutics in the 4th quarter valued at approximately $67,000. Jane Street Group LLC acquired a new position in Abeona Therapeutics during the third quarter worth $84,000. Oxford Asset Management LLP purchased a new position in shares of Abeona Therapeutics in the 4th quarter valued at about $118,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of Abeona Therapeutics in the third quarter valued at about $151,000. Hedge funds and other institutional investors own 80.56% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.